NASDAQ: GYRE - Gyre Therapeutics, Inc.

Lønnsomhet i seks måneder: +3.06%
Utbytte: 0.00%

Kampanjeplan Gyre Therapeutics, Inc.

Avansert tidsplan Enkel graf
Financial Markets by TradingView

Om selskapet Gyre Therapeutics, Inc.

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease.

flere detaljer
The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis. In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Legg til i sammenligningslisten
Legg til overvåkningsliste
Legg til portefølje
Legg til prisvarsel

IPO date 2006-04-12
ISIN US4037831033
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 0
Дивиденд ао 25.05
Сайт https://www.gyretx.com
Цена ао 16.79
Prisendring per dag: -5.18% (13.13)
Prisendring per uke: +11.76% (11.14)
Prisendring per måned: +6.41% (11.7)
Prisendring over 3 måneder: -2.43% (12.76)
Prisendring over seks måneder: +3.06% (12.08)
Prisendring per år: -51.54% (25.69)
Prisendring over 3 år: +516.34% (2.02)
Prisendring over 5 år: +12.36% (11.08)
Prisendring over 10 år: 0% (12.45)
Prisendring siden begynnelsen av året: -10.04% (13.84)
Alle parametere

Undervurdering

Navn Betydning Karakter
P/S 17.22 1
P/BV 140.07 1
P/E 0 0
EV/EBITDA 16.55 6
Total: 2.13

Effektivitet

Navn Betydning Karakter
ROA, % -79.74 0
ROE, % 587.14 10
Total: 5

Utbytte

Navn Betydning Karakter
Div yield, % 0 0
DSI 0.5 5
Total: 2.22

Plikt

Navn Betydning Karakter
Debt/EBITDA 0.0035 10
Total: 10

Vekstimpuls

Navn Betydning Karakter
Lønnsomhet Revenue, % 1890733.33 10
Lønnsomhet Ebitda, % -347.89 0
Lønnsomhet EPS, % 123.83 10
Total: 6
Flere detaljer

Institusjoner Volum Dele, %
Renaissance Technologies, LLC 39379 0.1
Geode Capital Management, LLC 17250 0.05
Vanguard Group Inc 13793 0.04
Blackrock Inc. 10250 0.03
Citigroup Inc. 7748 0.02
Morgan Stanley 6516 0.02
Kynam Capital Management, LP 6004 0.02
Northern Trust Corporation 5761 0.02
State Street Corporation 4840 0.01
Nantahala Capital Management, LLC 4520 0.01

ETF Dele, % Lønnsomhet for året, % Utbytte, %
iShares Morningstar Small Cap Value ETF 0.00477 26.7 2.50476
iShares Morningstar Small-Cap Value ETF 0.00477 201.65 2.50476
iShares Morningstar Small-Cap ETF 0.00416 30.1 1.60498
iShares Morningstar Small-Cap ETF 0.00416 391.25 1.60498
iShares Morningstar Small-Cap Growth ETF 0.00411 33.63 0.72598
iShares Morningstar Small-Cap Growth ETF 0.00411 587.89 0.72598

Veileder Stillingstittel Betaling Fødselsår
Dr. Han Ying Ph.D. CEO & Director 10.5k 1966 (59 år)
Mr. Songjiang Ma President & Director N/A 1956 (69 år)
Ms. Ruoyu Chen Chief Financial Officer 121.35k 1971 (54 år)
Mr. Weiguo Ye Chief Operating Officer 274.62k 1978 (47 år)
Ms. Seline E. Miller CPA Senior Vice President of Finance N/A 1970 (55 år)

Adresse: United States, San Diego. CA, 12770 High Bluff Drive - åpne i Google maps, åpne Yandex-kart
Nettsted: https://www.gyretx.com